← Eichor
Study identifier: NCT07166211 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Condition: Chronic Spontaneous Urticaria (CSU)  ·  Sponsor: Keymed Biosciences Co.Ltd

PhasePhase 2
Planned participants48
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.

This description comes directly from the study's public registry record.

Talk to the study team

Qian Jia  ·  86+028-88610620  ·  clinicaltrial@keymedbio.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tianjin Academy of Traditional Chinese Medicine Affiliate HospitalTianjin, Tianjin Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07166211